ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - ImmunityBio reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.26, and improved from a loss of $0.19 per share a year ago, representing an earnings surprise of 42.31% [1] - The company posted revenues of $7.55 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 13.54%, compared to revenues of $0.14 million in the same quarter last year [2] - Over the last four quarters, ImmunityBio has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - ImmunityBio shares have increased approximately 28.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $20.03 million, and for the current fiscal year, it is -$0.81 on revenues of $119.75 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which ImmunityBio belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can materially impact stock performance [5][8]